Gilde Healthcare
en nl de
  • Portfolio
  • Team
  • News
  • About us
  • Contact

News

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Follow @GildeHealthcare

Axonics® expands into stress urinary incontinence with the acquisition of Bulkamid®

March 1, 2021 – IRVINE, California US – Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, last week announced that…

Related to: Axonics Modulation Technologies

Ace Pharmaceuticals strengthens shareholders base

March 1, 2021 – Zeewolde, the Netherlands – Ace Pharmaceuticals (Ace), a specialized pharmaceutical company in medical need medicines, strengthens its shareholders base with the addition of Gilde Buy Out Partners and Gilde Healthcare. Founded in 1990 and based in Zeewolde, Ace focuses on the development,…

Related to: Ace Pharmaceuticals

LAVA Therapeutics Appoints Dr. Kapil Dhingra as Chairman of the Board of Directors in Advance of Lead Program Entering the Clinic

February 22, 2021 – Utrecht, The Netherlands and Philadelphia, USA – LAVA Therapeutics B.V., an early clinical-stage biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the appointment of Dr. Kapil Dhingra as chairman…

Related to: Lava Therapeutics

Acacia Pharma (EURONEXT: ACPH) raises EUR 27 million for US launch

February 19, 2021 – Cambridge, UK and Indianapolis, US – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or…

Related to: Acacia Pharma

Nyxoah and Vanderbilt University enter exclusive licensing agreement

February 2, 2021 – Utrecht (The Netherlands) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has signed an exclusive…

Related to: Nyxoah

Acacia Pharma launches BYFAVO™ in the United States for procedural sedation in adults undergoing medical procedures lasting 30 minutes or less

January 28, 2021 – Approximately 40 million procedures take place annually in the US that require the use of procedural sedation BYFAVO is the second Acacia Pharma product approved and launched in the US in the last year and extends its portfolio of new products targeting unmet needs in anesthesia Cambridge…

Related to: Acacia Pharma

Nyxoah announces full-body MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)

January 26, 2021 – Utecht (The Netherlands) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has received CE…

Related to: Nyxoah

Acacia Pharma wins BEL Company of the Year for the second consecutive year

January 20, 2021 – This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge (United Kingdom) and Utrecht (the Netherlands) – Acacia Pharma Group plc (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused…

Related to: Acacia Pharma

RAD-x adds Radiologisches Zentrum Lahnstein (RZL) to its group

January 19, 2021 – Utrecht (the Netherlands) – RAD-x is welcoming Radiologisches Zentrum Lahnstein (“RZL”) in its group. Radiologisches Zentrum Lahnstein is a provider of diagnostic imaging services in the region Koblenz, Germany. Its three radiologists and almost 30 staff serve the community in…

Related to: RAD-x

AM-Pharma announces enrollment and financing of COVID-19 cohort in phase III REVIVAL trial

January 8, 2021 – First patients with COVID-19 enrolled in the REVIVAL Phase III study COVID-19 patients with sepsis-associated acute kidney injury will be included in an exploratory cohort in the pivotal trial enrolling up to 1,600 SA-AKI patients overall RVO, an agency of the Dutch Ministry of…

Related to: AM-Pharma

Gilde Healthcare leads $28 million financing in Volta Medical to revolutionize persistent AFib ablation

January 6, 2021 – Marseille (France) - Utrecht (the Netherlands) – Volta Medical, a French-based HealthTech startup, pioneering novel artificial intelligence (AI) algorithms to treat cardiac arrythmias, today announced that it has successfully raised an 28 million USD financing round led by Gilde Healthcare.…

Related to: Volta Medical

Vesper Medical Announces First Enrollment in the VIVID Trial

December 1, 2020 – Vesper Medical announces initiation of pivotal clinical study for its next generation deep venous stent: The Vesper DUO Venous Stent System

Related to: Vesper Medical, Inc.

Gilde Healthcare participates in €51M series A financing of Noema Pharma

December 1, 2020 – €51 million to advance a pipeline of four clinical-stage product candidates in-licensed from Roche to treat orphan neurological disorders Highly experienced team leverages latest scientific discoveries in neuroscience Gilde Healthcare joins an international investor syndicate…

Related to: Noema Pharma

MercachemSyncom changes name to Symeres

November 19, 2020 – Nijmegen (The Netherlands) – MercachemSyncom today announced that it will change its name and operate under the registered trade name of Symeres.   The new name reflects the strategic evolution of the company, with the growth of integrated drug discovery and development services,…

Related to: Symeres

Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin15 (IL-15) monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases

November 16, 2020 – Dose-escalation study to evaluate safety, biological and early clinical effect of CALY-002 in healthy volunteers and patients with Celiac Disease and Eosinophilic Esophagitis Amsterdam, The Netherlands - Calypso Biotech, a company developing Interleukin-15-targeted biologics, today…

Related to: Calypso Biotech B.V.

Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry

November 13, 2020 – IRVINE, Calif. — (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced follow-up results of the first 230…

Related to: Inari Medical, Inc.

AM-PHARMA Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury

November 12, 2020 – Trial to confirm potential of AM-Pharma’s recombinant alkaline phosphatase to reduce mortality, as demonstrated in the Phase II STOP-AKI study Target enrolment of up to 1,600 SA-AKI patients at ICUs in Europe, United Kingdom and North America Utrecht, The Netherlands – AM-Pharma…

Related to: AM-Pharma

Drug discovery CRO MercachemSyncom adds biology services through acquisition

November 9, 2020 – Utrecht (the Netherlands) – Gilde Healthcare portfolio company MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, today announced that it has acquired Admescope Ltd., a provider of ADME-Tox services, based in Oulu (Finland) and Södertälje…

Related to: Symeres

Eargo, Inc. announces pricing of Initial Public Offering

October 16, 2020 – San Jose (CA, US) – Eargo, Inc. (“Eargo”), a medical device company dedicated to improving the quality of life of people with hearing loss, announced today the pricing of its initial public offering of 7,851,852 shares of its common stock at a public offering price of $18.00 per share.…

Related to: Eargo, Inc.

Nyxoah raises up to €85 million (US$100M) in successful initial public offering

September 17, 2020 – NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, SOUTH AFRICA, CANADA, JAPAN Utrecht (The Netherlands) – Gilde Healthcare company Nyxoah (the “Company”) a health-technology company focused…

Related to: Nyxoah

Lava Therapeutics announces $83 million series C financing to advance novel gamma-delta T cell engager programs

September 17, 2020 – Utrecht (The Netherlands) and Philadelphia – Gilde Healthcare company Lava Therapeutics announced the closing of an oversubscribed $83 million (€71 million) Series C financing to fund the advancement of its pipeline and platform. The financing was co-led by new investors Novo Ventures…

Related to: Lava Therapeutics

Nyxoah announces intention to launch an Initial Public Offering on Euronext Brussels

August 27, 2020 – Mont-Saint-Guibert (Belgium) and Utrecht (The Netherlands) – Nyxoah S.A. (“Nyxoah” or the “Company”) a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions, today announces its…

Related to: Nyxoah

Acacia Pharma commercially launches BARHEMSYS® in the US for the treatment of prevention of postoperative nausea & vomiting

August 24, 2020 – Cambridge (UK) and Indianapolis (US) – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures,…

Related to: Acacia Pharma

Acacia Pharma raises €25M to launch BARHEMSYS® and BYFAVO™ in the US

August 14, 2020 – Cambridge (UK) and Indianapolis (US) – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures,…

Related to: Acacia Pharma

Lumeon raises $30M to fuel growth in the US

August 11, 2020 – Boston (Massachusetts, US) and Utrecht (The Netherlands) – Lumeon, the leader in care pathway orchestration, today announced that it has closed $30M in Series D funding led by new investors Optum Ventures and Endeavour Vision, with participation from current investors Gilde Healthcare,…

Related to: Lumeon

Gilde Healthcare

Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare's venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare's private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.

Investment Philosophy

Gilde Healthcare invests in fast growing, innovative businesses delivering better care at lower cost.

  • Home
  • Portfolio
  • Team
  • News
  • Contact
  • Imprint
  • Privacy Policy
  • SFDR Disclosure